Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 05/03/2019
Entire Document
 


Case 18-10518-KG    Doc 1081    Filed 04/29/19     Page 6 of 11

 

In re: Orexigen Therapeutics, Inc.

   Case No. 18- 10518 (KG)

Debtor

   Reporting Period: March 1, 2019 - March 31, 2019

 

MOR - 1b

Schedule of Debtor Bank Account Balances (1)

For the Period: March 1, 2019 - March 31, 2019

(Unaudited)

 

$ USD ‘000s
Debtor
   Bank    Last Four Digits
Account No.
    Account Description       Beginning
Balance
3/1/2019
    Ending
Balance
    3/31/2019
 

 

 

Orexigen Therapeutics, Inc.

  

Silicon Valley Bank

     6813    

General checking

    $       $  

Orexigen Therapeutics, Inc.

  

Silicon Valley Bank

     1180    

Zero-balance lockbox

           

Orexigen Therapeutics, Inc.

  

Silicon Valley Bank

     3036    

Sweep account

    25,924       25,171  

Orexigen Therapeutics, Inc.

  

Silicon Valley Bank

     7307    

Utility adequate assurance

           

Orexigen Therapeutics, Inc.

  

Silicon Valley Bank

     5177    

Collateral

    100       100  
         

 

 

 

Total Bank Account Balances

            $ 26,024       $ 25,271  
         

 

 

 

Notes:

 

(1) The Consolidated Schedule of Cash Receipts and Disbursements (MOR-1) and Schedule of Disbursements by Debtor Entity (MOR-la) represent book balances while MOR-lb represents bank balances. The balances differ primarily due to the bank’s delayed recording of intrabank activity between the general checking and sweep accounts.